Skip to main content

Anti-Rheumatic Rx

      GLORIA Study Pred vs PBO in >65yrs RA x 2 years. 451 Pts & DAS28 4.5. 79% on DMARDs (14% biologics)
      Upside: Lowe

      Dr. John Cush RheumNow

      3 years 3 months ago
      GLORIA Study Pred vs PBO in >65yrs RA x 2 years. 451 Pts & DAS28 4.5. 79% on DMARDs (14% biologics) Upside: Lower DAS28 -0.37 & less Xray progression -1.7 Sharp units Downside: 24% more AE (mild infxns), signif.small lowering of lumbar BMD -1% You Decide https://t.co/RRq0WcFsXz https://t.co/xLxjPPSMhh
      PsA: A heart throb or stopper?
      Dr. Jack Cush reviews the top abstracts from EULAR 2022  As chosen by me with the  aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz.  Speaking of social media…
      Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent rheumatoid arthritis occurring in at-risk individuals. While it is often a point of substantive discussion at EULAR, this year’s meeting in Copenhagen provided further data on how therapy might useful before patients develop rheumatoid arthritis (RA), particularly for those at particularly high risk.
      Despite updated gout management guidelines from European (EULAR) and British (BSR) societies, treatment of gout is suboptimal with regard to the use of urate-lowering therapy (ULT) and normalizing serum uric acid (< 6.0 mg/dl) levels.
      An Annals of Internal Medicine review has shown that clinical trials and cohort studies of cannabinoids use for chronic pain may be associated with short-term improvements in chronic pain but come with an increased risk for dizziness and sedation. Studies of long-term outcomes and product formulation effects are lacking.
      ORAL Surveillance: the fallout
      The British Society of Rheumatology has published their updated 2022 recommendations for the use of biologics and targeted synthetic treatments in patients with psoriatic arthritis. These guidelines follow initial treatment with a single conventional systemic disease-modifying anti-rheumatic drug, typically methotrexate typically. They noted that up to 50% of people with PsA require biologic or targeted synthetic (b/ts)DMARD therapy. 
      ×